http://hl7.org/fhir/uv/ebm/PublicationRecord/179616
type: PublicationRecord
resource definition: 1.0
resource definition: .0
node role: treeRoot
id:
  v: 179616
meta:
  version id:
    v: 24
  last updated:
    v: 2026-06-26T20:08:11.083Z
  profile:
    v: http://hl7.org/fhir/uv/ebm/StructureDefinition/journal-article-citation
    l: journal-article-citation
language:
  v: en
text:
  status:
    v: extensions
  div:
    v: Generated Narrative: PublicationRecord 179616 version: 24; Last updated: 2026-06-26 20:08:11+0000 Profile: JournalArticleCitation ArtifactPublicationStatus: Active url: https://fevir.net/resources/PublicationRecord/179616 identifier: FEvIR Object Identifier/179616, https://pubmed.ncbi.nlm.nih.gov/26244877 title: 26244877 Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer. status: Active author: Computable Publishing®: MEDLINE-to-FEvIR Converter: publisher: Computable Publishing LLC contact: support@computablepublishing.com description: This Citation Resource is referenced in an example for the EBMonFHIR Implementation Guide. UseContexts - Code Value[x] * Citation Classification Type: fevir-platform-use (FEvIR Platform Use) Medline Base copyright: Copyright the Authors else Computable Publishing LLC. Noncommercial use permitted with CC BY-NC-SA 4.0 (https://creativecommons.org/licenses/by-nc-sa/4.0/). Commercial use permitted as agreed in Terms of Use (https://fevir.net/termsofuse). approvalDate: 2015-08-25 lastReviewDate: 2024-08-05 classification type: Citation Source classifier: MEDLINE classification type: MEDLINE Citation Owner classifier: National Library of Medicine, Index Section currentState: Medline Citation Status of Medline, PubMed PublicationStatus of ppublish statusDate activity: PubMed Pubstatus of Entrez period: ?? --> 2015-08-06 06:00:00+0000 statusDate activity: PubMed Pubstatus of Pubmed period: ?? --> 2015-08-06 06:00:00+0000 statusDate activity: PubMed Pubstatus of Medline period: ?? --> 2015-08-26 06:00:00+0000 statusDate activity: PubMed Pubstatus of PMC release period: ?? --> 2016-02-20 citedArtifact identifier: https://pubmed.ncbi.nlm.nih.gov/26244877, mid/NIHMS719565, https://www.ncbi.nlm.nih.gov/pmc//PMC4562797, https://doi.org/10.1056/NEJMoa1503747 relatedIdentifier: <a href="http://terminology.hl7.org/7.3.0/NamingSystem-ClinicalTrials-Gov.html" title="The U.S. National Institutes of Health, Department of Health and Huma…
contained: Practitioner
  id:
    v: contributor0
  name:
    family:
      v: Sweeney
    given:
      v: Christopher J
contained: Practitioner
  id:
    v: contributor1
  name:
    family:
      v: Chen
    given:
      v: Yu-Hui
contained: Practitioner
  id:
    v: contributor2
  name:
    family:
      v: Carducci
    given:
      v: Michael
contained: Practitioner
  id:
    v: contributor3
  name:
    family:
      v: Liu
    given:
      v: Glenn
contained: Practitioner
  id:
    v: contributor4
  name:
    family:
      v: Jarrard
    given:
      v: David F
contained: Practitioner
  id:
    v: contributor5
  name:
    family:
      v: Eisenberger
    given:
      v: Mario
contained: Practitioner
  id:
    v: contributor6
  name:
    family:
      v: Wong
    given:
      v: Yu-Ning
contained: Practitioner
  id:
    v: contributor7
  name:
    family:
      v: Hahn
    given:
      v: Noah
contained: Practitioner
  id:
    v: contributor8
  name:
    family:
      v: Kohli
    given:
      v: Manish
contained: Practitioner
  id:
    v: contributor9
  name:
    family:
      v: Cooney
    given:
      v: Matthew M
contained: Practitioner
  id:
    v: contributor10
  name:
    family:
      v: Dreicer
    given:
      v: Robert
contained: Practitioner
  id:
    v: contributor11
  name:
    family:
      v: Vogelzang
    given:
      v: Nicholas J
contained: Practitioner
  id:
    v: contributor12
  name:
    family:
      v: Picus
    given:
      v: Joel
contained: Practitioner
  id:
    v: contributor13
  name:
    family:
      v: Shevrin
    given:
      v: Daniel
contained: Practitioner
  id:
    v: contributor14
  name:
    family:
      v: Hussain
    given:
      v: Maha
contained: Practitioner
  id:
    v: contributor15
  name:
    family:
      v: Garcia
    given:
      v: Jorge A
contained: Practitioner
  id:
    v: contributor16
  name:
    family:
      v: DiPaola
    given:
      v: Robert S
contained: ArtifactAssessment
  id:
    v: meshHeading0
  artifact: Reference
    l: #
    reference:
      v: #
    type:
      v: PublicationRecord
      l: PublicationRecord
  content:
    type:
      text:
        v: components (if present) include qualifier codings
    classifier: D000328
    free to share:
      v: true
  content:
    type:
      text:
        v: components (if present) include qualifier codings
    classifier: D000368
    free to share:
      v: true
  content:
    type:
      text:
        v: components (if present) include qualifier codings
    classifier: D000369
    free to share:
      v: true
  content:
    type:
      text:
        v: components (if present) include qualifier codings
    classifier: D000726
    free to share:
      v: true
    component:
      classifier: Q000009
    component:
      classifier: Q000627
  content:
    type:
      text:
        v: components (if present) include qualifier codings
    classifier: D000970

v: mesh-heading

v: MeSH heading

v: D000328

v: Adult

v: false

v: qualifier

v: is not a major topic

v: mesh-heading

v: MeSH heading

v: D000368

v: Aged

v: false

v: qualifier

v: is not a major topic

v: mesh-heading

v: MeSH heading

v: D000369

v: Aged, 80 and over

v: false

v: qualifier

v: is not a major topic

v: mesh-heading

v: MeSH heading

v: D000726

v: Androgen Antagonists

v: false

v: qualifier

v: is not a major topic

v: qualifier

system:
  v: https://www.nlm.nih.gov/mesh
  l: mesh
code:
  v: Q000009
display:
  v: adverse effects

text:
  v: is Major topic

coding:
  system:
    v: http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl
    l: Thesaurus.owl
  code:
    v: C49487
  display:
    v: No

v: qualifier

system:
  v: https://www.nlm.nih.gov/mesh
  l: mesh
code:
  v: Q000627
display:
  v: therapeutic use

text:
  v: is Major topic

coding:
  system:
    v: http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl
    l: Thesaurus.owl
  code:
    v: C49488
  display:
    v: Yes

v: mesh-heading

v: MeSH heading

D000970
coding:
  system:
    v: https://www.nlm.nih.gov/mesh
    l: mesh
  code:
    v: D000970
  display:
    v: Antineoplastic Agents
  user selected:
    v: false

v: true

type:
  text:
    v: qualifier
classifier:
  text:
    v: is not a major topic

type:
  text:
    v: qualifier
classifier: Q000009
  coding:
    system:
      v: https://www.nlm.nih.gov/mesh
      l: mesh
    code:
      v: Q000009
    display:
      v: adverse effects
component:
  type:
    text:
      v: is Major topic
  classifier:
    coding:
      system:
        v: http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl
        l: Thesaurus.owl
      code:
        v: C49487
      display:
        v: No

type:
  text:
    v: qualifier
classifier: Q000627
  coding:
    system:
      v: https://www.nlm.nih.gov/mesh
      l: mesh
    code:
      v: Q000627
    display:
      v: therapeutic use
component:
  type:
    text:
      v: is Major topic
  classifier:
    coding:
      system:
        v: http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl
        l: Thesaurus.owl
      code:
        v: C49488
      display:
        v: Yes

type:
  coding:
    system:
      v: http://terminology.hl7.org/CodeSystem/cited-artifact-classification-type
      l: cited-artifact-classification-type
    code:
      v: mesh-heading
    display:
      v: MeSH heading
  text:
    v: components (if present) include qualifier codings
classifier: http://id.nlm.nih.gov/mesh/D000077143
  coding:
    system:
      v: https://www.nlm.nih.gov/mesh
      l: mesh
    code:
      v: D000077143
    display:
      v: Docetaxel
    user selected:
      v: false
free to share:
  v: true
component:
  type:
    text:
      v: qualifier
  classifier:
    text:
      v: is not a major topic

type:
  coding:
    system:
      v: http://terminology.hl7.org/CodeSystem/cited-artifact-classification-type
      l: cited-artifact-classification-type
    code:
      v: mesh-heading
    display:
      v: MeSH heading
  text:
    v: components (if present) include qualifier codings
classifier: D004359
  coding:
    system:
      v: https://www.nlm.nih.gov/mesh
      l: mesh
    code:
      v: D004359
    display:
      v: Drug Therapy, Combination
    user selected:
      v: false
free to share:
  v: true
component:
  type:
    text:
      v: qualifier
  classifier:
    text:
      v: is not a major topic

type:
  coding:
    system:
      v: http://terminology.hl7.org/CodeSystem/cited-artifact-classification-type
      l: cited-artifact-classification-type
    code:
      v: mesh-heading
    display:
      v: MeSH heading
  text:
    v: components (if present) include qualifier codings
classifier: D005500
  coding:
    system:
      v: https://www.nlm.nih.gov/mesh
      l: mesh
    code:
      v: D005500
    display:
      v: Follow-Up Studies
    user selected:
      v: false
free to share:
  v: true
component:
  type:
    text:
      v: qualifier
  classifier:
    text:
      v: is not a major topic

type:
  coding:
    system:
      v: http://terminology.hl7.org/CodeSystem/cited-artifact-classification-type
      l: cited-artifact-classification-type
    code:
      v: mesh-heading
    display:
      v: MeSH heading
  text:
    v: components (if present) include qualifier codings
classifier: D006801
  coding:
    system:
      v: https://www.nlm.nih.gov/mesh
      l: mesh
    code:
      v: D006801
    display:
      v: Humans
    user selected:
      v: false
free to share:
  v: true
component:
  type:
    text:
      v: qualifier
  classifier:
    text:
      v: is not a major topic

type:
  coding:
    system:
      v: http://terminology.hl7.org/CodeSystem/cited-artifact-classification-type
      l: cited-artifact-classification-type
    code:
      v: mesh-heading
    display:
      v: MeSH heading
  text:
    v: components (if present) include qualifier codings
classifier: D053208
  coding:
    system:
      v: https://www.nlm.nih.gov/mesh
      l: mesh
    code:
      v: D053208
    display:
      v: Kaplan-Meier Estimate
    user selected:
      v: false
free to share:
  v: true
component:
  type:
    text:
      v: qualifier
  classifier:
    text:
      v: is not a major topic

type:
  coding:
    system:
      v: http://terminology.hl7.org/CodeSystem/cited-artifact-classification-type
      l: cited-artifact-classification-type
    code:
      v: mesh-heading
    display:
      v: MeSH heading
  text:
    v: components (if present) include qualifier codings
classifier: D008297
  coding:
    system:
      v: https://www.nlm.nih.gov/mesh
      l: mesh
    code:
      v: D008297
    display:
      v: Male
    user selected:
      v: false
free to share:
  v: true
component:
  type:
    text:
      v: qualifier
  classifier:
    text:
      v: is not a major topic

type:
  coding:
    system:
      v: http://terminology.hl7.org/CodeSystem/cited-artifact-classification-type
      l: cited-artifact-classification-type
    code:
      v: mesh-heading
    display:
      v: MeSH heading
  text:
    v: components (if present) include qualifier codings
classifier: D008875
  coding:
    system:
      v: https://www.nlm.nih.gov/mesh
      l: mesh
    code:
      v: D008875
    display:
      v: Middle Aged
    user selected:
      v: false
free to share:
  v: true
component:
  type:
    text:
      v: qualifier
  classifier:
    text:
      v: is not a major topic

type:
  coding:
    system:
      v: http://terminology.hl7.org/CodeSystem/cited-artifact-classification-type
      l: cited-artifact-classification-type
    code:
      v: mesh-heading
    display:
      v: MeSH heading
  text:
    v: components (if present) include qualifier codings
classifier: D009503
  coding:
    system:
      v: https://www.nlm.nih.gov/mesh
      l: mesh
    code:
      v: D009503
    display:
      v: Neutropenia
    user selected:
      v: false
free to share:
  v: true
component:
  type:
    text:
      v: qualifier
  classifier:
    text:
      v: is not a major topic
component:
  type:
    text:
      v: qualifier
  classifier: Q000139
    coding:
      system:
        v: https://www.nlm.nih.gov/mesh
        l: mesh
      code:
        v: Q000139
      display:
        v: chemically induced
  component:
    type:
      text:
        v: is Major topic
component:
  type:
    text:
      v: qualifier
  classifier: Q000453
    coding:
      system:
        v: https://www.nlm.nih.gov/mesh
        l: mesh
      code:
        v: Q000453
      display:
        v: epidemiology
  component:
    type:
      text:
        v: is Major topic

v: C49487

v: No

v: C49487

v: No

type:
  coding:
    system:
      v: http://terminology.hl7.org/CodeSystem/cited-artifact-classification-type
      l: cited-artifact-classification-type
    code:
      v: mesh-heading
    display:
      v: MeSH heading
  text:
    v: components (if present) include qualifier codings
classifier: D017430
  coding:
    system:
      v: https://www.nlm.nih.gov/mesh
      l: mesh
    code:
      v: D017430
    display:
      v: Prostate-Specific Antigen
    user selected:
      v: false
free to share:
  v: true
component:
  type:
    text:
      v: qualifier
  classifier:
    text:
      v: is not a major topic
component:
  type:
    text:
      v: qualifier
  classifier: Q000097
    coding:
      system:
        v: https://www.nlm.nih.gov/mesh
        l: mesh
      code:
        v: Q000097
      display:
        v: blood
  component:
    type:
      text:
        v: is Major topic

v: C49487

v: No

type:
  coding:
    system:
      v: http://terminology.hl7.org/CodeSystem/cited-artifact-classification-type
      l: cited-artifact-classification-type
    code:
      v: mesh-heading
    display:
      v: MeSH heading
  text:
    v: components (if present) include qualifier codings
classifier: D011471
  coding:
    system:
      v: https://www.nlm.nih.gov/mesh
      l: mesh
    code:
      v: D011471
    display:
      v: Prostatic Neoplasms
    user selected:
      v: false
free to share:
  v: true
component:
  type:
    text:
      v: qualifier
  classifier:
    text:
      v: is not a major topic
component:
  type:
    text:
      v: qualifier
  classifier: Q000188
    coding:
      system:
        v: https://www.nlm.nih.gov/mesh
        l: mesh
      code:
        v: Q000188
      display:
        v: drug therapy
  component:
    type:
      text:
        v: is Major topic
component:
  type:
    text:
      v: qualifier
  classifier: Q000401
    coding:
      system:
        v: https://www.nlm.nih.gov/mesh
        l: mesh
      code:
        v: Q000401
      display:
        v: mortality
  component:
    type:
      text:
        v: is Major topic
component:
  type:
    text:
      v: qualifier
  classifier: Q000473
    coding:
      system:
        v: https://www.nlm.nih.gov/mesh
        l: mesh
      code:
        v: Q000473
      display:
        v: pathology
  component:
    type:
      text:
        v: is Major topic

v: C49488

v: Yes

v: C49487

v: No

v: C49487

v: No

type:
  coding:
    system:
      v: http://terminology.hl7.org/CodeSystem/cited-artifact-classification-type
      l: cited-artifact-classification-type
    code:
      v: mesh-heading
    display:
      v: MeSH heading
  text:
    v: components (if present) include qualifier codings
classifier: D043823
  coding:
    system:
      v: https://www.nlm.nih.gov/mesh
      l: mesh
    code:
      v: D043823
    display:
      v: Taxoids
    user selected:
      v: false
free to share:
  v: true
component:
  type:
    text:
      v: qualifier
  classifier:
    text:
      v: is not a major topic
component:
  type:
    text:
      v: qualifier
  classifier: Q000009
    coding:
      system:
        v: https://www.nlm.nih.gov/mesh
        l: mesh
      code:
        v: Q000009
      display:
        v: adverse effects
  component:
    type:
      text:
        v: is Major topic
component:
  type:
    text:
      v: qualifier
  classifier: Q000627
    coding:
      system:
        v: https://www.nlm.nih.gov/mesh
        l: mesh
      code:
        v: Q000627
      display:
        v: therapeutic use
  component:
    type:
      text:
        v: is Major topic

v: C49487

v: No

v: C49488

v: Yes

url:
  v: http://hl7.org/fhir/uv/ebm/StructureDefinition/artifact-publication-status
  l: artifact-publication-status
value: CodeableConcept
  coding:
    system:
      v: http://terminology.hl7.org/CodeSystem/cited-artifact-status-type
      l: cited-artifact-status-type
    code:
      v: active
    display:
      v: Active

type:
  coding:
    system:
      v: http://terminology.hl7.org/CodeSystem/v2-0203
      l: v2-0203
    code:
      v: ACSN
    display:
      v: Accession ID
  text:
    v: FEvIR Object Identifier
system:
  v: https://fevir.net/FOI
  l: FOI
value:
  v: 179616
assigner:
  display:
    v: Computable Publishing LLC

system:
  v: https://pubmed.ncbi.nlm.nih.gov
  l: pubmed.ncbi.nlm.nih.gov
value:
  v: 26244877

v: 26244877 Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer.

v: active

name:
  v: Computable Publishing®: MEDLINE-to-FEvIR Converter

v: Computable Publishing LLC

telecom:
  system:
    v: email

v: This Citation Resource is referenced in an example for the EBMonFHIR Implementation Guide.

code:
  system:
    v: http://terminology.hl7.org/CodeSystem/citation-classification-type
    l: citation-classification-type
  code:
    v: fevir-platform-use
  display:
    v: FEvIR Platform Use
value: CodeableConcept
  coding:
    system:
      v: http://terminology.hl7.org/CodeSystem/citation-artifact-classifier
      l: citation-artifact-classifier
    code:
      v: medline-base
    display:
      v: Medline Base
    user selected:
      v: false

v: Copyright the Authors else Computable Publishing LLC. Noncommercial use permitted with CC BY-NC-SA 4.0 (https://creativecommons.org/licenses/by-nc-sa/4.0/). Commercial use permitted as agreed in Terms of Use (https://fevir.net/termsofuse).

v: 2015-08-25

v: 2024-08-05

type:
  coding:
    system:
      v: http://terminology.hl7.org/CodeSystem/citation-classification-type
      l: citation-classification-type
    code:
      v: citation-source
    display:
      v: Citation Source
classifier:
  text:
    v: MEDLINE

type:
  coding:
    system:
      v: http://terminology.hl7.org/CodeSystem/citation-classification-type
      l: citation-classification-type
    code:
      v: medline-owner
    display:
      v: MEDLINE Citation Owner
classifier:
  coding:
    system:
      v: https://www.nlm.nih.gov/bsd/licensee/elements_descriptions.html#owner_value
      l: owner value
    code:
      v: NLM
    display:
      v: National Library of Medicine, Index Section
    user selected:
      v: false

coding:
  system:
    v: http://hl7.org/fhir/uv/ebm-incubator/CodeSystem/publicationrecord-status-type
    l: publicationrecord-status-type
  code:
    v: medline-medline
  display:
    v: Medline Citation Status of Medline

coding:
  system:
    v: http://hl7.org/fhir/uv/ebm-incubator/CodeSystem/publicationrecord-status-type
    l: publicationrecord-status-type
  code:
    v: pubmed-publication-status-ppublish
  display:
    v: PubMed PublicationStatus of ppublish

activity:
  coding:
    system:
      v: http://hl7.org/fhir/uv/ebm-incubator/CodeSystem/publicationrecord-status-type
      l: publicationrecord-status-type
    code:
      v: pubmed-pubstatus-entrez
    display:
      v: PubMed Pubstatus of Entrez
period:
  end:
    v: 2015-08-06T06:00:00.000Z

activity:
  coding:
    system:
      v: http://hl7.org/fhir/uv/ebm-incubator/CodeSystem/publicationrecord-status-type
      l: publicationrecord-status-type
    code:
      v: pubmed-pubstatus-pubmed
    display:
      v: PubMed Pubstatus of Pubmed
period:
  end:
    v: 2015-08-06T06:00:00.000Z

activity:
  coding:
    system:
      v: http://hl7.org/fhir/uv/ebm-incubator/CodeSystem/publicationrecord-status-type
      l: publicationrecord-status-type
    code:
      v: pubmed-pubstatus-medline
    display:
      v: PubMed Pubstatus of Medline
period:
  end:
    v: 2015-08-26T06:00:00.000Z

activity:
  coding:
    system:
      v: http://hl7.org/fhir/uv/ebm-incubator/CodeSystem/publicationrecord-status-type
      l: publicationrecord-status-type
    code:
      v: pubmed-pubstatus-pmc-release
    display:
      v: PubMed Pubstatus of PMC release
period:
  end:
    v: 2016-02-20

identifier:
  system:
    v: https://pubmed.ncbi.nlm.nih.gov
    l: pubmed.ncbi.nlm.nih.gov
  value:
    v: 26244877
identifier:
  type:
    coding:
      system:
        v: http://terminology.hl7.org/CodeSystem/v2-0203
        l: v2-0203
      code:
        v: ACSN
      display:
        v: Accession ID
    text:
      v: mid
  value:
    v: NIHMS719565
identifier:
  system:
    v: https://www.ncbi.nlm.nih.gov/pmc/
    l: pmc
  value:
    v: PMC4562797
identifier:
  system:
    v: https://doi.org
    l: doi.org
  value:
    v: 10.1056/NEJMoa1503747
related identifier:
  system:
    v: https://clinicaltrials.gov/nctid
    l: nctid
  value:
    v: NCT00309985
  assigner:
    display:
      v: ClinicalTrials.gov
title:
  type:
    coding:
      system:
        v: http://hl7.org/fhir/title-type
        l: title-type
      code:
        v: primary
      display:
        v: Primary title
  language:
    v: en
  text:
    v: Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer.
abstract:
  type:
    coding:
      system:
        v: http://hl7.org/fhir/cited-artifact-abstract-type
        l: cited-artifact-abstract-type
      code:
        v: primary-human-use
      display:
        v: Primary human use
  text:
    v: **BACKGROUND:** Androgen-deprivation therapy (ADT) has been the backbone of treatment for metastatic prostate cancer since the 1940s. We assessed whether concomitant treatment with ADT plus docetaxel would result in longer overall survival than that with ADT alone. **METHODS:** We assigned men with metastatic, hormone-sensitive prostate cancer to receive either ADT plus docetaxel (at a dose of 75 mg per square meter of body-surface area every 3 weeks for six cycles) or ADT alone. The primary objective was to test the hypothesis that the median overall survival would be 33.3% longer among patients receiving docetaxel added to ADT early during therapy than among patients receiving ADT alone. **RESULTS:** A total of 790 patients (median age, 63 years) underwent randomization. After a median follow-up of 28.9 months, the median overall survival was 13.6 months longer with ADT plus docetaxel (combination therapy) than with ADT alone (57.6 months vs. 44.0 months; hazard ratio for death in the combination group, 0.61; 95% confidence interval [CI], 0.47 to 0.80; P<0.001). The median time to biochemical, symptomatic, or radiographic progression was 20.2 months in the combination group, as compared with 11.7 months in the ADT-alone group (hazard ratio, 0.61; 95% CI, 0.51 to 0.72; P<0.001). The rate of a prostate-specific antigen level of less than 0.2 ng per milliliter at 12 months was 27.7% in the combination group versus 16.8% in the ADT-alone group (P<0.001). In the combination group, the rate of grade 3 or 4 febrile neutropenia was 6.2%, the rate of grade 3 or 4 infection with neutropenia was 2.3%, and the rate of grade 3 sensory neuropathy and of grade 3 motor neuropathy was 0.5%. **CONCLUSIONS:** Six cycles of docetaxel at the beginning of ADT for metastatic prostate cancer resulted in significantly longer overall survival than that with ADT alone. (Funded by the National Cancer Institute and others; ClinicalTrials.gov number, NCT00309985.).
relates to:
  type:
    coding:
      system:
        v: http://terminology.hl7.org/CodeSystem/artifact-relationship-type
        l: artifact-relationship-type
      code:
        v: cites
      display:
        v: Cites
  citation:
    v: Huggins C, Hodges CV. Studies on prostatic cancer. I. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. Cancer Res. 1941;1:293–7.
relates to:
  type:
    coding:
      system:
        v: http://terminology.hl7.org/CodeSystem/artifact-relationship-type
        l: artifact-relationship-type
      code:
        v: cites
      display:
        v: Cites
  classifier:
    coding:
      system:
        v: http://terminology.hl7.org/CodeSystem/citation-artifact-classifier
        l: citation-artifact-classifier
      code:
        v: D016428
      display:
        v: Journal Article
  citation:
    v: Prostate Cancer Trialists’ Collaborative Group. Maximum androgen blockade in advanced prostate cancer: an overview of the randomised trials. Lancet. 2000;355:1491–8.
  target: Uri
    v: https://pubmed.ncbi.nlm.nih.gov/10801170/
    l: https://pubmed.ncbi.nlm.nih.gov/10801170/
relates to:
  type:
    coding:
      system:
        v: http://terminology.hl7.org/CodeSystem/artifact-relationship-type
        l: artifact-relationship-type
      code:
        v: cites
      display:
        v: Cites
  classifier:
    coding:
      system:
        v: http://terminology.hl7.org/CodeSystem/citation-artifact-classifier
        l: citation-artifact-classifier
      code:
        v: D016428
      display:
        v: Journal Article
  citation:
    v: Samson DJ, Seidenfeld J, Schmitt B, et al. Systematic review and meta-analysis of monotherapy compared with combined androgen blockade for patients with advanced prostate carcinoma. Cancer. 2002;95:361–76.
  target: Uri
    v: https://pubmed.ncbi.nlm.nih.gov/12124837/
    l: https://pubmed.ncbi.nlm.nih.gov/12124837/
relates to:
  type:
    coding:
      system:
        v: http://terminology.hl7.org/CodeSystem/artifact-relationship-type
        l: artifact-relationship-type
      code:
        v: cites
      display:
        v: Cites
  classifier:
    coding:
      system:
        v: http://terminology.hl7.org/CodeSystem/citation-artifact-classifier
        l: citation-artifact-classifier
      code:
        v: D016428
      display:
        v: Journal Article
  citation:
    v: Hussain M, Tangen CM, Berry DL, et al. Intermittent versus continuous androgen deprivation in prostate cancer. N Engl J Med. 2013;368:1314–25.
  target: Uri
    v: https://pubmed.ncbi.nlm.nih.gov/23550669/
    l: https://pubmed.ncbi.nlm.nih.gov/23550669/
relates to:
  type:
    coding:
      system:
        v: http://terminology.hl7.org/CodeSystem/artifact-relationship-type
        l: artifact-relationship-type
      code:
        v: cites
      display:
        v: Cites
  classifier:
    coding:
      system:
        v: http://terminology.hl7.org/CodeSystem/citation-artifact-classifier
        l: citation-artifact-classifier
      code:
        v: D016428
      display:
        v: Journal Article
  citation:
    v: Tangen CM, Hussain MH, Higano CS, et al. Improved overall survival trends of men with newly diagnosed M1 prostate cancer: a SWOG phase III trial experience (S8494, S8894 and S9346) J Urol. 2012;188:1164–9.
  target: Uri
    v: https://pubmed.ncbi.nlm.nih.gov/22921015/
    l: https://pubmed.ncbi.nlm.nih.gov/22921015/
relates to:
  type:
    coding:
      system:
        v: http://terminology.hl7.org/CodeSystem/artifact-relationship-type
        l: artifact-relationship-type
      code:
        v: cites
      display:
        v: Cites
  classifier:
    coding:
      system:
        v: http://terminology.hl7.org/CodeSystem/citation-artifact-classifier
        l: citation-artifact-classifier
      code:
        v: D016428
      display:
        v: Journal Article
  citation:
    v: Wu JN, Fish KM, Evans CP, Devere White RW, Dall’Era MA. No improvement noted in overall or cause-specific survival for men presenting with metastatic prostate cancer over a 20-year period. Cancer. 2014;120:818–23.
  target: Uri
    v: https://pubmed.ncbi.nlm.nih.gov/24258693/
    l: https://pubmed.ncbi.nlm.nih.gov/24258693/
relates to:
  type:
    coding:
      system:
        v: http://terminology.hl7.org/CodeSystem/artifact-relationship-type
        l: artifact-relationship-type
  target: Uri

v: cites

v: Cites

coding:
  system:
    v: http://terminology.hl7.org/CodeSystem/citation-artifact-classifier
    l: citation-artifact-classifier
  code:
    v: D016428
  display:
    v: Journal Article

v: Petrylak DP, Tangen CM, Hussain MH, et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med. 2004;351:1513–20.

type:
  coding:
    system:
      v: http://terminology.hl7.org/CodeSystem/artifact-relationship-type
      l: artifact-relationship-type
    code:
      v: cites
    display:
      v: Cites
classifier:
  coding:
    system:
      v: http://terminology.hl7.org/CodeSystem/citation-artifact-classifier
      l: citation-artifact-classifier
    code:
      v: D016428
    display:
      v: Journal Article
citation:
  v: Tannock IF, de Wit R, Berry WR, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med. 2004;351:1502–12.
target: Uri
  v: https://pubmed.ncbi.nlm.nih.gov/15470213/
  l: https://pubmed.ncbi.nlm.nih.gov/15470213/

type:
  coding:
    system:
      v: http://terminology.hl7.org/CodeSystem/artifact-relationship-type
      l: artifact-relationship-type
    code:
      v: cites
    display:
      v: Cites
classifier:
  coding:
    system:
      v: http://terminology.hl7.org/CodeSystem/citation-artifact-classifier
      l: citation-artifact-classifier
    code:
      v: D016428
    display:
      v: Journal Article
citation:
  v: Millikan RE, Wen S, Pagliaro LC, et al. Phase III trial of androgen ablation with or without three cycles of systemic chemotherapy for advanced prostate cancer. J Clin Oncol. 2008;26:5936–42.
target: Uri
  v: https://pubmed.ncbi.nlm.nih.gov/19029421/
  l: https://pubmed.ncbi.nlm.nih.gov/19029421/

type:
  coding:
    system:
      v: http://terminology.hl7.org/CodeSystem/artifact-relationship-type
      l: artifact-relationship-type
    code:
      v: cites
    display:
      v: Cites
classifier:
  coding:
    system:
      v: http://terminology.hl7.org/CodeSystem/citation-artifact-classifier
      l: citation-artifact-classifier
    code:
      v: D016428
    display:
      v: Journal Article
citation:
  v: Gravis G, Fizazi K, Joly F, et al. Androgen-deprivation therapy alone or with docetaxel in non-castrate metastatic prostate cancer (GETUG-AFU 15): a randomised, open-label, phase 3 trial. Lancet Oncol. 2013;14:149–58.
target: Uri
  v: https://pubmed.ncbi.nlm.nih.gov/23306100/
  l: https://pubmed.ncbi.nlm.nih.gov/23306100/

type:
  coding:
    system:
      v: http://terminology.hl7.org/CodeSystem/artifact-relationship-type
      l: artifact-relationship-type
    code:
      v: cites
    display:
      v: Cites
classifier:
  coding:
    system:
      v: http://terminology.hl7.org/CodeSystem/citation-artifact-classifier
      l: citation-artifact-classifier
    code:
      v: D016428
    display:
      v: Journal Article
citation:
  v: Crawford ED, Eisenberger MA, McLeod DG, et al. A controlled trial of leuprolide with and without flutamide in prostatic carcinoma. N Engl J Med. 1989;321:419–24.
target: Uri
  v: https://pubmed.ncbi.nlm.nih.gov/2503724/
  l: https://pubmed.ncbi.nlm.nih.gov/2503724/

type:
  coding:
    system:
      v: http://terminology.hl7.org/CodeSystem/artifact-relationship-type
      l: artifact-relationship-type
    code:
      v: cites
    display:
      v: Cites
classifier:
  coding:
    system:
      v: http://terminology.hl7.org/CodeSystem/citation-artifact-classifier
      l: citation-artifact-classifier
    code:
      v: D016428
    display:
      v: Journal Article
citation:
  v: Eisenberger MA, Blumenstein BA, Crawford ED, et al. Bilateral orchiectomy with or without flutamide for metastatic prostate cancer. N Engl J Med. 1998;339:1036–42.
target: Uri
  v: https://pubmed.ncbi.nlm.nih.gov/9761805/
  l: https://pubmed.ncbi.nlm.nih.gov/9761805/

type:
  coding:
    system:
      v: http://terminology.hl7.org/CodeSystem/artifact-relationship-type
      l: artifact-relationship-type
    code:
      v: cites
    display:
      v: Cites
classifier:
  coding:
    system:
      v: http://terminology.hl7.org/CodeSystem/citation-artifact-classifier
      l: citation-artifact-classifier
    code:
      v: D016428
    display:
      v: Journal Article
citation:
  v: Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada J Natl Cancer Inst. 2000;92:205–16.
target: Uri
  v: https://pubmed.ncbi.nlm.nih.gov/10655437/
  l: https://pubmed.ncbi.nlm.nih.gov/10655437/

type:
  coding:
    system:
      v: http://terminology.hl7.org/CodeSystem/artifact-relationship-type
      l: artifact-relationship-type
    code:
      v: cites
    display:
      v: Cites
citation:
  v: Jennison CTB. Statistical approaches to interim monitoring of medical trials: a review and commentary. Stat Sci. 1990;5:299–317.

type:
  coding:
    system:
      v: http://terminology.hl7.org/CodeSystem/artifact-relationship-type
      l: artifact-relationship-type
    code:
      v: cites
    display:
      v: Cites
citation:
  v: Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958;53:457–81.

type:
  coding:
    system:
      v: http://terminology.hl7.org/CodeSystem/artifact-relationship-type
      l: artifact-relationship-type
    code:
      v: cites
    display:
      v: Cites
citation:
  v: Cox DR. Regression models and life-tables. J R Stat Soc B. 1972;34:187–220.

type:
  coding:
    system:
      v: http://terminology.hl7.org/CodeSystem/artifact-relationship-type
      l: artifact-relationship-type
    code:
      v: cites
    display:
      v: Cites
classifier:
  coding:
    system:
      v: http://terminology.hl7.org/CodeSystem/citation-artifact-classifier
      l: citation-artifact-classifier
    code:
      v: D016428
    display:
      v: Journal Article
citation:
  v: Mantel N. Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep. 1966;50:163–70.
target: Uri
  v: https://pubmed.ncbi.nlm.nih.gov/5910392/
  l: https://pubmed.ncbi.nlm.nih.gov/5910392/

type:
  coding:
    system:
      v: http://terminology.hl7.org/CodeSystem/artifact-relationship-type
      l: artifact-relationship-type
    code:
      v: cites
    display:
      v: Cites
citation:
  v: Cox D. Analysis of binary data. London: Methuen and Co; 1970.

type:
  coding:
    system:
      v: http://terminology.hl7.org/CodeSystem/artifact-relationship-type
      l: artifact-relationship-type
    code:
      v: cites
    display:
      v: Cites
classifier:
  coding:
    system:
      v: http://terminology.hl7.org/CodeSystem/citation-artifact-classifier
      l: citation-artifact-classifier
    code:
      v: D016428
    display:
      v: Journal Article
citation:
  v: de Bono JS, Logothetis CJ, Molina A, et al. Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med. 2011;364:1995–2005.
target: Uri
  v: https://pubmed.ncbi.nlm.nih.gov/21612468/
  l: https://pubmed.ncbi.nlm.nih.gov/21612468/

type:
  coding:
    system:
      v: http://terminology.hl7.org/CodeSystem/artifact-relationship-type
      l: artifact-relationship-type
    code:
      v: cites
    display:
      v: Cites
classifier:
  coding:
    system:
      v: http://terminology.hl7.org/CodeSystem/citation-artifact-classifier
      l: citation-artifact-classifier
    code:
      v: D016428
    display:
      v: Journal Article
citation:
  v: Ryan CJ, Smith MR, de Bono JS, et al. Abiraterone in metastatic prostate cancer without previous chemotherapy. N Engl J Med. 2013;368:138–48.
target: Uri
  v: https://pubmed.ncbi.nlm.nih.gov/23228172/
  l: https://pubmed.ncbi.nlm.nih.gov/23228172/

type:
  coding:
    system:
      v: http://terminology.hl7.org/CodeSystem/artifact-relationship-type
      l: artifact-relationship-type
    code:
      v: cites
    display:
      v: Cites
classifier:
  coding:
    system:
      v: http://terminology.hl7.org/CodeSystem/citation-artifact-classifier
      l: citation-artifact-classifier
    code:
      v: D016428
    display:
      v: Journal Article
citation:
  v: Beer TM, strong AJ, Rathkopf DE, et al. Enzalutamide in metastatic prostate cancer before chemotherapy. N Engl J Med. 2014;371:424–33.
target: Uri
  v: https://pubmed.ncbi.nlm.nih.gov/24881730/
  l: https://pubmed.ncbi.nlm.nih.gov/24881730/

type:
  coding:
    system:
      v: http://terminology.hl7.org/CodeSystem/artifact-relationship-type
      l: artifact-relationship-type
    code:
      v: cites
    display:
      v: Cites
classifier:
  coding:
    system:
      v: http://terminology.hl7.org/CodeSystem/citation-artifact-classifier
      l: citation-artifact-classifier
    code:
      v: D016428
    display:
      v: Journal Article
citation:
  v: Scher HI, Fizazi K, Saad F, et al. Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med. 2012;367:1187–97.
target: Uri
  v: https://pubmed.ncbi.nlm.nih.gov/22894553/
  l: https://pubmed.ncbi.nlm.nih.gov/22894553/

type:
  coding:
    system:
      v: http://terminology.hl7.org/CodeSystem/artifact-relationship-type
      l: artifact-relationship-type
    code:
      v: cites
    display:
      v: Cites
classifier:
  coding:
    system:
      v: http://terminology.hl7.org/CodeSystem/citation-artifact-classifier
      l: citation-artifact-classifier
    code:
      v: D016428
    display:
      v: Journal Article
citation:
  v: Kantoff PW, Higano CS, Shore ND, et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med. 2010;363:411–22.
target: Uri
  v: https://pubmed.ncbi.nlm.nih.gov/20818862/
  l: https://pubmed.ncbi.nlm.nih.gov/20818862/

type:
  coding:
    system:
      v: http://terminology.hl7.org/CodeSystem/artifact-relationship-type
      l: artifact-relationship-type
    code:
      v: cites
    display:
      v: Cites
classifier:
  coding:
    system:
      v: http://terminology.hl7.org/CodeSystem/citation-artifact-classifier
      l: citation-artifact-classifier
    code:
      v: D016428
    display:
      v: Journal Article
citation:
  v: de Bono JS, Oudard S, Ozguroglu M, et al. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. Lancet. 2010;376:1147–54.
target: Uri
  v: https://pubmed.ncbi.nlm.nih.gov/20888992/
  l: https://pubmed.ncbi.nlm.nih.gov/20888992/

type:
  coding:
    system:
      v: http://terminology.hl7.org/CodeSystem/artifact-relationship-type
      l: artifact-relationship-type
    code:
      v: cites
    display:
      v: Cites
classifier:
  coding:
    system:
      v: http://terminology.hl7.org/CodeSystem/citation-artifact-classifier
      l: citation-artifact-classifier
    code:
      v: D016428
    display:
      v: Journal Article
citation:
  v: Parker C, Nilsson S, Heinrich D, et al. Alpha emitter radium-223 and survival in metastatic prostate cancer. N Engl J Med. 2013;369:213–23.
target: Uri
  v: https://pubmed.ncbi.nlm.nih.gov/23863050/
  l: https://pubmed.ncbi.nlm.nih.gov/23863050/

type:
  coding:
    system:
      v: http://terminology.hl7.org/CodeSystem/artifact-relationship-type
      l: artifact-relationship-type
    code:
      v: cites
    display:
      v: Cites
classifier:
  coding:
    system:
      v: http://terminology.hl7.org/CodeSystem/citation-artifact-classifier
      l: citation-artifact-classifier
    code:
      v: D016428
    display:
      v: Journal Article
citation:
  v: James ND, Spears MR, Clarke NW, et al. Survival with newly diagnosed metastatic prostate cancer in the “docetaxel era”: data from 917 patients in the control of the STAMPEDE trial (MRC PR08, CRUK/06/019) Eur Urol. 2015;67:1028–38.
target: Uri
  v: https://pubmed.ncbi.nlm.nih.gov/25301760/
  l: https://pubmed.ncbi.nlm.nih.gov/25301760/

type:
  coding:
    system:
      v: http://terminology.hl7.org/CodeSystem/artifact-relationship-type
      l: artifact-relationship-type
    code:
      v: comment-in
    display:
      v: Has Comment In
classifier: D016420
  coding:
    system:
      v: https://www.nlm.nih.gov/mesh
      l: mesh
    code:
      v: D016420
    display:
      v: Comment
    user selected:
      v: false
citation:
  v: BMJ. 2015 Aug 05;351:h4253. doi: 10.1136/bmj.h4253.
target: Uri
  v: https://pubmed.ncbi.nlm.nih.gov/26251343/
  l: https://pubmed.ncbi.nlm.nih.gov/26251343/

type:
  coding:
    system:
      v: http://terminology.hl7.org/CodeSystem/artifact-relationship-type
      l: artifact-relationship-type
    code:
      v: comment-in
    display:
      v: Has Comment In
classifier: D016420
  coding:
    system:
      v: https://www.nlm.nih.gov/mesh
      l: mesh
    code:
      v: D016420
    display:
      v: Comment
    user selected:
      v: false
citation:
  v: Nat Rev Clin Oncol. 2015 Oct;12(10):563. doi: 10.1038/nrclinonc.2015.145.
target: Uri
  v: https://pubmed.ncbi.nlm.nih.gov/26305034/
  l: https://pubmed.ncbi.nlm.nih.gov/26305034/

type:
  coding:
    system:
      v: http://terminology.hl7.org/CodeSystem/artifact-relationship-type
      l: artifact-relationship-type
    code:
      v: comment-in
    display:
      v: Has Comment In
classifier: D016420
  coding:
    system:
      v: https://www.nlm.nih.gov/mesh
      l: mesh
    code:
      v: D016420
    display:
      v: Comment
    user selected:
      v: false
citation:
  v: Nat Rev Urol. 2015 Dec;12(12):656-8. doi: 10.1038/nrurol.2015.255.
target: Uri
  v: https://pubmed.ncbi.nlm.nih.gov/26526753/
  l: https://pubmed.ncbi.nlm.nih.gov/26526753/

type:
  coding:
    system:
      v: http://terminology.hl7.org/CodeSystem/artifact-relationship-type
      l: artifact-relationship-type
    code:
      v: comment-in
    display:
      v: Has Comment In
classifier: D016420
  coding:
    system:
      v: https://www.nlm.nih.gov/mesh
      l: mesh
    code:
      v: D016420
    display:
      v: Comment
    user selected:
      v: false
citation:
  v: Nat Rev Clin Oncol. 2015 Dec;12(12):687-8. doi: 10.1038/nrclinonc.2015.192.
target: Uri
  v: https://pubmed.ncbi.nlm.nih.gov/26552950/
  l: https://pubmed.ncbi.nlm.nih.gov/26552950/

type:
  coding:
    system:
      v: http://terminology.hl7.org/CodeSystem/artifact-relationship-type
      l: artifact-relationship-type
    code:
      v: comment-in
    display:
      v: Has Comment In
classifier: D016420
  coding:
    system:
      v: https://www.nlm.nih.gov/mesh
      l: mesh
    code:
      v: D016420
    display:
      v: Comment
    user selected:
      v: false
citation:
  v: BMC Med. 2015 Dec 22;13:304. doi: 10.1186/s12916-015-0543-9.
target: Uri
  v: https://pubmed.ncbi.nlm.nih.gov/26695172/
  l: https://pubmed.ncbi.nlm.nih.gov/26695172/

type:
  coding:
    system:
      v: http://terminology.hl7.org/CodeSystem/artifact-relationship-type
      l: artifact-relationship-type
    code:
      v: comment-in
    display:
      v: Has Comment In
classifier: D016420
  coding:
    system:
      v: https://www.nlm.nih.gov/mesh
      l: mesh
    code:
      v: D016420
    display:
      v: Comment
    user selected:
      v: false
citation:
  v: J Urol. 2016 Jan;195(1):94. doi: 10.1016/j.juro.2015.10.055.
target: Uri
  v: https://pubmed.ncbi.nlm.nih.gov/26699961/
  l: https://pubmed.ncbi.nlm.nih.gov/26699961/

type:
  coding:
    system:
      v: http://terminology.hl7.org/CodeSystem/artifact-relationship-type
      l: artifact-relationship-type
    code:
      v: comment-in
    display:
      v: Has Comment In
classifier: D016420
  coding:
    system:
      v: https://www.nlm.nih.gov/mesh
      l: mesh
    code:
      v: D016420
    display:
      v: Comment
    user selected:
      v: false
citation:
  v: N Engl J Med. 2016 Jan 21;374(3):287. doi: 10.1056/NEJMc1511800.
target: Uri
  v: https://pubmed.ncbi.nlm.nih.gov/26789883/
  l: https://pubmed.ncbi.nlm.nih.gov/26789883/

type:
  coding:
    system:
      v: http://terminology.hl7.org/CodeSystem/artifact-relationship-type
      l: artifact-relationship-type
    code:
      v: comment-in
    display:
      v: Has Comment In
classifier: D016420
  coding:
    system:
      v: https://www.nlm.nih.gov/mesh
      l: mesh
    code:
      v: D016420
    display:
      v: Comment
    user selected:
      v: false
citation:
  v: N Engl J Med. 2016 Jan 21;374(3):286. doi: 10.1056/NEJMc1511800.
target: Uri
  v: https://pubmed.ncbi.nlm.nih.gov/26789884/
  l: https://pubmed.ncbi.nlm.nih.gov/26789884/

type:
  coding:
    system:
      v: http://terminology.hl7.org/CodeSystem/artifact-relationship-type
      l: artifact-relationship-type
    code:
      v: comment-in
    display:
      v: Has Comment In
classifier: D016420
  coding:
    system:
      v: https://www.nlm.nih.gov/mesh
      l: mesh
    code:
      v: D016420
    display:
      v: Comment
    user selected:
      v: false
citation:
  v: Eur Urol. 2016 Mar;69(3):540. doi: 10.1016/j.eururo.2015.12.027.
target: Uri
  v: https://pubmed.ncbi.nlm.nih.gov/26867727/
  l: https://pubmed.ncbi.nlm.nih.gov/26867727/

type:
  coding:
    system:
      v: http://terminology.hl7.org/CodeSystem/artifact-relationship-type
      l: artifact-relationship-type
    code:
      v: comment-in
    display:
      v: Has Comment In
classifier: D016420
  coding:
    system:
      v: https://www.nlm.nih.gov/mesh
      l: mesh
    code:
      v: D016420
    display:
      v: Comment
    user selected:
      v: false
citation:
  v: Eur Urol. 2016 Apr;69(4):755-6. doi: 10.1016/j.eururo.2016.01.020.
target: Uri
  v: https://pubmed.ncbi.nlm.nih.gov/26972499/
  l: https://pubmed.ncbi.nlm.nih.gov/26972499/

type:
  coding:
    system:
      v: http://terminology.hl7.org/CodeSystem/artifact-relationship-type
      l: artifact-relationship-type
    code:
      v: comment-in
    display:
      v: Has Comment In
classifier: D016420
  coding:
    system:
      v: https://www.nlm.nih.gov/mesh
      l: mesh
    code:
      v: D016420
    display:
      v: Comment
    user selected:
      v: false
citation:
  v: Eur Urol. 2016 Jan;69(1):178. doi: 10.1016/j.eururo.2015.10.037.
target: Uri
  v: https://pubmed.ncbi.nlm.nih.gov/27099882/
  l: https://pubmed.ncbi.nlm.nih.gov/27099882/

type:
  coding:
    system:
      v: http://terminology.hl7.org/CodeSystem/artifact-relationship-type
      l: artifact-relationship-type
    code:
      v: comment-in
    display:
      v: Has Comment In
classifier: D016420
  coding:
    system:
      v: https://www.nlm.nih.gov/mesh
      l: mesh
    code:
      v: D016420
    display:
      v: Comment
    user selected:
      v: false
citation:
  v: Urol Oncol. 2017 Mar;35(3):123. doi: 10.1016/j.urolonc.2016.12.021.
target: Uri
  v: https://pubmed.ncbi.nlm.nih.gov/28159490/
  l: https://pubmed.ncbi.nlm.nih.gov/28159490/

published in:
  type:
    coding:
      system:
        v: http://terminology.hl7.org/CodeSystem/published-in-type
        l: published-in-type
      code:
        v: D020492
      display:
        v: Periodical
  identifier:
    type:
      text:
        v: Electronic ISSN Type
    system:
      v: https://portal.issn.org
      l: portal.issn.org
    value:
      v: 1533-4406
  identifier:
    type:
      text:
        v: ISOAbbreviation
    system:
      v: https://www.issn.org/services/online-services/access-to-the-ltwa/
      l: access-to-the-ltwa
    value:
      v: N Engl J Med
  identifier:
    type:
      text:
        v: ISSN Linking
    system:
      v: https://www.issn.org/understanding-the-issn/assignment-rules/the-issn-l-for-publications-on-multiple-media/
      l: the-issn-l-for-publications-on-multiple-media
    value:
      v: 0028-4793
  identifier:
    type:
      text:
        v: Medline Title Abbreviation
    system:
      v: https://www.nlm.nih.gov/tsd/cataloging/contructitleabbre.html
      l: contructitleabbre.html
    value:
      v: N Engl J Med
  identifier:
    type:
      text:
        v: NLM Unique ID
    system:
      v: https://locatorplus.gov/cgi-bin/Pwebrecon.cgi
      l: https://locatorplus.gov/cgi-bin/Pwebrecon.cgi
    value:
      v: 0255562
  title:
    v: The New England journal of medicine
  publisher location:
    v: United States
cited medium:
  coding:
    system:
      v: http://terminology.hl7.org/CodeSystem/cited-medium
      l: cited-medium
    code:
      v: internet
    display:
      v: Internet
volume:
  v: 373
issue:
  v: 8
article date:
  v: 2015-08-20
publication date text:
  v: 2015-Aug-20
page string:
  v: 737-46

v: Electronic

v: Electronic

v: XX

v: Organization identifier

v: XX

v: Organization identifier

v: XX

v: Organization identifier

v: XX

v: Organization identifier

cited medium:
  coding:
    system:
      v: http://terminology.hl7.org/CodeSystem/cited-medium
      l: cited-medium
    code:
      v: internet-without-issue
    display:
      v: Internet without issue
article date:
  v: 2015-08-05

classifier:
  coding:
    system:
      v: http://hl7.org/fhir/artifact-url-classifier
      l: artifact-url-classifier
    code:
      v: abstract
    display:
      v: Abstract
url:
  v: https://pubmed.ncbi.nlm.nih.gov/26244877/
  l: https://pubmed.ncbi.nlm.nih.gov/26244877/

classifier:
  coding:
    system:
      v: http://hl7.org/fhir/artifact-url-classifier
      l: artifact-url-classifier
    code:
      v: doi-based
    display:
      v: DOI Based
url:
  v: https://doi.org/10.1056/NEJMoa1503747
  l: NEJMoa1503747

type:
  coding:
    system:
      v: http://terminology.hl7.org/CodeSystem/cited-artifact-classification-type
      l: cited-artifact-classification-type
    code:
      v: publishing-model
    display:
      v: Publishing Model
    user selected:
      v: false
classifier:
  coding:
    system:
      v: http://terminology.hl7.org/CodeSystem/citation-artifact-classifier
      l: citation-artifact-classifier
    code:
      v: Print-Electronic
    display:
      v: Print Electronic
    user selected:
      v: false

type:
  coding:
    system:
      v: http://terminology.hl7.org/CodeSystem/cited-artifact-classification-type
      l: cited-artifact-classification-type
    code:
      v: chemical
    display:
      v: Chemical
    user selected:
      v: false
classifier: D000726
  coding:
    system:
      v: https://www.nlm.nih.gov/mesh
      l: mesh
    code:
      v: D000726
    display:
      v: Androgen Antagonists
    user selected:
      v: false
classifier: D000970
  coding:
    system:
      v: https://www.nlm.nih.gov/mesh
      l: mesh
    code:
      v: D000970
    display:
      v: Antineoplastic Agents
    user selected:
      v: false
classifier: D043823
  coding:
    system:
      v: https://www.nlm.nih.gov/mesh
      l: mesh
    code:
      v: D043823
    display:
      v: Taxoids
    user selected:
      v: false
classifier: http://id.nlm.nih.gov/mesh/D000077143
  coding:
    system:
      v: https://www.cas.org/support/documentation/chemical-substances
      l: chemical-substances
    code:
      v: 15H5577CQD
    user selected:
      v: false
  coding:
    system:
      v: https://www.nlm.nih.gov/mesh
      l: mesh
    code:
      v: D000077143
    display:
      v: Docetaxel
    user selected:
      v: false
classifier: D017430
  coding:
    system:
      v: https://www.cas.org/support/documentation/chemical-substances
      l: chemical-substances
    code:
      v: EC 3.4.21.77
    user selected:
      v: false
  coding:
    system:
      v: https://www.nlm.nih.gov/mesh
      l: mesh
    code:
      v: D017430
    display:
      v: Prostate-Specific Antigen
    user selected:
      v: false

type:
  coding:
    system:
      v: http://terminology.hl7.org/CodeSystem/cited-artifact-classification-type
      l: cited-artifact-classification-type
    code:
      v: mesh-heading
    display:
      v: MeSH heading
artifact assessment:
  l: meshHeading0
  reference:
    v: #meshHeading0
  type:
    v: ArtifactAssessment
    l: ArtifactAssessment

type:
  coding:
    system:
      v: http://terminology.hl7.org/CodeSystem/cited-artifact-classification-type
      l: cited-artifact-classification-type
    code:
      v: publication-type
    display:
      v: Publication type
classifier: D016428
  coding:
    system:
      v: https://www.nlm.nih.gov/mesh
      l: mesh
    code:
      v: D016428
    display:
      v: Journal Article
    user selected:
      v: false
classifier: D016448
  coding:
    system:
      v: https://www.nlm.nih.gov/mesh
      l: mesh
    code:
      v: D016448
    display:
      v: Multicenter Study
    user selected:
      v: false
classifier: D016449
  coding:
    system:
      v: https://www.nlm.nih.gov/mesh
      l: mesh
    code:
      v: D016449
    display:
      v: Randomized Controlled Trial
    user selected:
      v: false
classifier: D052061
  coding:
    system:
      v: https://www.nlm.nih.gov/mesh
      l: mesh
    code:
      v: D052061
    display:
      v: Research Support, N.I.H., Extramural
    user selected:
      v: false
classifier: D013485
  coding:
    system:
      v: https://www.nlm.nih.gov/mesh
      l: mesh
    code:
      v: D013485
    display:
      v: Research Support, Non-U.S. Gov't
    user selected:
      v: false

type:
  coding:
    system:
      v: http://terminology.hl7.org/CodeSystem/cited-artifact-classification-type
      l: cited-artifact-classification-type
    code:
      v: knowledge-artifact-type
    display:
      v: Knowledge Artifact Type
    user selected:
      v: false
classifier:
  coding:
    system:
      v: http://terminology.hl7.org/CodeSystem/citation-artifact-classifier
      l: citation-artifact-classifier
    code:
      v: D016428
    display:
      v: Journal Article
    user selected:
      v: false
artifact assessment:
  display:
    v: Classifier added by Computable Publishing LLC

type:
  coding:
    system:
      v: http://terminology.hl7.org/CodeSystem/cited-artifact-classification-type
      l: cited-artifact-classification-type
    code:
      v: citation-subset
    display:
      v: Citation subset
    user selected:
      v: false
classifier:
  coding:
    system:
      v: https://www.nlm.nih.gov/bsd/licensee/elements_descriptions.html#citationsubset
      l: citationsubset
    code:
      v: IM
    display:
      v: IM
    user selected:
      v: false

complete:
  v: true
entry:
  contributor:
    l: contributor0
    reference:
      v: #contributor0
    type:
      v: Practitioner
      l: Practitioner
    display:
      v: Sweeney CJ
  forename initials:
    v: CJ
  affiliation:
    display:
      v: From the Department of Medicine (C.J.S.) and the Department of Biostatistics and Computational Biology (Y.-H.C.), Dana-Farber Cancer Institute, Boston; Harvard Medical School, Boston (C.J.S.); Johns Hopkins University, Baltimore (M.C., M.E.); University of Wisconsin Carbone Cancer Center (G.L., D.F.J.) and School of Medicine and Public Health (D.F.J.), Madison; Fox Chase Cancer Center, Temple University Health System, Philadelphia (Y.-N.W.); Indiana University Melvin and Bren Simon Cancer Center, Indianapolis (N.H.); Mayo Clinic, Rochester, MN (M.K.); University Hospitals Case Medical Center, Seidman Cancer Center (M.M.C.), and Cleveland Clinic Taussig Cancer Institute (J.A.G.) - both in Cleveland; University of Virginia Cancer Center, Charlottesville (R.D.); Comprehensive Cancer Centers of Nevada, Las Vegas (N.J.V.); Siteman Cancer Center, Washington University School of Medicine, St. Louis (J.P.); NorthShore University HealthSystem, Evanston, IL (D.S.); University of Michigan Comprehensive Cancer Center, Ann Arbor (M.H.); and Rutgers Cancer Institute of New Jersey, New Brunswick (R.S.D.).
entry:
  contributor:
    l: contributor1
    reference:
      v: #contributor1
    type:
      v: Practitioner
      l: Practitioner
    display:
      v: Chen YH
  forename initials:
    v: YH
entry:
  contributor:
    l: contributor2
    reference:
      v: #contributor2
    type:
      v: Practitioner
      l: Practitioner
    display:
      v: Carducci M
  forename initials:
    v: M
entry:
  contributor:
    l: contributor3
    reference:
      v: #contributor3
    type:
      v: Practitioner
      l: Practitioner
    display:
      v: Liu G
  forename initials:
    v: G
entry:
  contributor:
    l: contributor4
    reference:
      v: #contributor4
    type:
      v: Practitioner
      l: Practitioner
    display:
      v: Jarrard DF
  forename initials:
    v: DF
entry:
  contributor:
    l: contributor5
    reference:
      v: #contributor5
    type:
      v: Practitioner
      l: Practitioner
    display:
      v: Eisenberger M
  forename initials:
    v: M
entry:
  contributor:
    l: contributor6
    reference:
      v: #contributor6
    type:
      v: Practitioner
      l: Practitioner
    display:
      v: Wong YN
  forename initials:
    v: YN
entry:
  contributor:
    l: contributor7
    reference:
      v: #contributor7
    type:
      v: Practitioner
      l: Practitioner
    display:
      v: Hahn N
  forename initials:
    v: N
entry:
  contributor:
    l: contributor8
    reference:
      v: #contributor8
    type:
      v: Practitioner
      l: Practitioner
    display:
      v: Kohli M
  forename initials:
    v: M
entry:
  contributor:
    l: contributor9
    reference:
      v: #contributor9
    type:
      v: Practitioner
      l: Practitioner
    display:
      v: Cooney MM
  forename initials:
    v: MM
entry:
  contributor:
    l: contributor10
    reference:
      v: #contributor10
    type:
      v: Practitioner
      l: Practitioner
    display:
      v: Dreicer R
  forename initials:
    v: R
entry:
  contributor:
    l: contributor11
    reference:
      v: #contributor11
    type:
      v: Practitioner
      l: Practitioner
    display:
      v: Vogelzang NJ
  forename initials:
    v: NJ
entry:
  contributor:
    l: contributor12
    reference:
      v: #contributor12
    type:
      v: Practitioner
      l: Practitioner
    display:
      v: Picus J
  forename initials:
    v: J
entry:
  contributor:
    l: contributor13
    reference:
      v: #contributor13
    type:
      v: Practitioner
      l: Practitioner
    display:
      v: Shevrin D
  forename initials:
    v: D
entry:
  contributor:
    l: contributor14
    reference:
      v: #contributor14
    type:
      v: Practitioner
      l: Practitioner
    display:
      v: Hussain M
  forename initials:
    v: M
entry:
  contributor:
    l: contributor15
    reference:
      v: #contributor15
    type:
      v: Practitioner
      l: Practitioner
    display:
      v: Garcia JA
  forename initials:
    v: JA
entry:
  contributor:
    l: contributor16
    reference:
      v: #contributor16

v: Practitioner
l: Practitioner

v: DiPaola RS

v: RS